Additional file 2 of Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape

Additional file 2. Table 1: (Part 1) List of Most Mutated Genes validated in >10% of 23 T/N pairs and >10% of all 43 ACC patients. (Part 2) List of Validated Driver Mutations in <10% of 43 ACC Patients. Table 2: A, Alterations in Chromatin Remodeling Genes or Genes Controlling Epigenetic Processes. B, Alterations in DNA Repair Genes. Table 3: 769 Differentially Expressed Genes (DEG), upregulated (289) and downregulated (480) in ACC compared to NA. Table 4: IPA prediction of upstream regulators based on microarray expression data comparing 57 ACC samples vs. 5 normal adrenal samples. Table 5: Top Differentially Expressed MicroRNAs (DEM), up- or down-regulated in ACC compared to NA.

附加文件2。表1：（第1部分）在23对肿瘤-正常（T/N）配对样本中突变检出率>10%，且在全部43例肾上腺皮质癌（ACC, Adrenocortical Carcinoma）患者中突变检出率>10%的经验证高频突变基因列表；（第2部分）在43例ACC患者中突变检出率<10%的经验证驱动基因突变列表。表2：A，染色质重塑基因或表观遗传调控基因的变异情况；B，DNA修复基因的变异情况。表3：769个差异表达基因（DEG, Differentially Expressed Genes），其中肾上腺皮质癌相较于正常肾上腺（NA, Normal Adrenal）组织，上调基因289个、下调基因480个。表4：基于基因芯片（microarray）表达数据的Ingenuity通路分析（IPA, Ingenuity Pathway Analysis）上游调控因子预测结果，该分析比较了57例ACC样本与5例正常肾上腺样本。表5：排名靠前的差异表达微小RNA（DEM, Differentially Expressed MicroRNAs），其在肾上腺皮质癌组织相较于正常肾上腺组织中呈上调或下调表达。